Cargando…
Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade
Extra domain B splice variant of fibronectin (EDB+FN) is an extracellular matrix protein (ECM) deposited by tumor-associated fibroblasts, and is associated with tumor growth, angiogenesis, and invasion. We hypothesized that EDB+FN is a safe and abundant target for therapeutic intervention with an an...
Autores principales: | Hooper, Andrea T., Marquette, Kimberly, Chang, Chao-Pei Betty, Golas, Jonathon, Jain, Sadhana, Lam, My-Hanh, Guffroy, Magali, Leal, Mauricio, Falahatpisheh, Hadi, Mathur, Divya, Chen, Ting, Kelleher, Kerry, Khandke, Kiran, Muszynska, Elwira, Loganzo, Frank, Rosfjord, Edward, Lucas, Judy, Kan, Zhengyan, Subramanyam, Chakrapani, O'Donnell, Christopher, Neri, Dario, Gerber, Hans-Peter, May, Chad, Sapra, Puja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9446899/ https://www.ncbi.nlm.nih.gov/pubmed/35793468 http://dx.doi.org/10.1158/1535-7163.MCT-22-0099 |
Ejemplares similares
-
Targeted Nanofitin-drug Conjugates Achieve Efficient Tumor Delivery and Therapeutic Effect in an EGFR(pos) Mouse Xenograft Model
por: Huet, Simon, et al.
Publicado: (2023) -
Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists
por: Grinkevitch, Vera, et al.
Publicado: (2022) -
Antibody–Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization
por: Buongervino, Samantha, et al.
Publicado: (2021) -
A FZD7-specific Antibody–Drug Conjugate Induces Ovarian Tumor Regression in Preclinical Models
por: Do, Myan, et al.
Publicado: (2022) -
First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer
por: Pegram, Mark D., et al.
Publicado: (2021)